Antitumor therapeutic effects of a genetically engineered Salmonella typhimurium harboring TNF-alpha in mice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Won Suck | - |
dc.contributor.author | Chae, Yang Seok | - |
dc.contributor.author | Hong, Juyeon | - |
dc.contributor.author | Park, Yong Keun | - |
dc.date.accessioned | 2021-09-07T14:30:11Z | - |
dc.date.available | 2021-09-07T14:30:11Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2011-03 | - |
dc.identifier.issn | 0175-7598 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/112921 | - |
dc.description.abstract | Although the use of TNF-alpha in the treatment of cancer is restricted due to its non-specific cytotoxicity and narrow range of applications to different cancers in clinical trials, we investigated a safe anti-cancer drug by the use of engineered bacterial capsule harboring TNF-alpha. The engineered bacterial capsule was designed to target cancer cells, promote a tumor-suppressive environment, and increase the efficacy of existing cancer treatments, including chemotherapy, radiotherapy, and cell therapy. The engineered bacterial capsule was constructed with Salmonella capsulizing TNF-alpha protein, which was produced and capsulized by Salmonella to reduce side effects of the protein. This bacterial capsule induced a tumor-suppressive environment through the activation of natural killer cells. Engineered bacterial capsule invaded tumor cells, released TNF-alpha, and induced apoptosis of tumor cells without apparent side effects. In a murine melanoma model, the bacterial capsule of TNF-alpha significantly inhibited tumor growth by 80-100% and prolonged the survival of the mice. When tested in combination with chemotherapy (cisplatin), antibiotics, and vaccine, recombinant microbial treatment increased the anti-tumor effects of existing therapies. The anti-tumor effects of the bacterial capsule of TNF-alpha were also observed in cervical cancer, melanoma, breast cancer, colon cancer, and renal carcinoma. These results suggest that the bacterial capsule of TNF-alpha is a promising strategy for TNF-alpha treatment. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | TUMOR-TARGETED SALMONELLA | - |
dc.subject | ESCHERICHIA-COLI K12 | - |
dc.subject | CELL LUNG-CANCER | - |
dc.subject | ATTENUATED SALMONELLA | - |
dc.subject | NECROSIS-FACTOR | - |
dc.subject | PHASE-I | - |
dc.subject | CYTOSINE DEAMINASE | - |
dc.subject | CISPLATIN TOXICITY | - |
dc.subject | ADJUVANT THERAPY | - |
dc.subject | INTERFERON-ALPHA | - |
dc.title | Antitumor therapeutic effects of a genetically engineered Salmonella typhimurium harboring TNF-alpha in mice | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Won Suck | - |
dc.contributor.affiliatedAuthor | Chae, Yang Seok | - |
dc.contributor.affiliatedAuthor | Park, Yong Keun | - |
dc.identifier.doi | 10.1007/s00253-010-3006-4 | - |
dc.identifier.scopusid | 2-s2.0-79952575222 | - |
dc.identifier.wosid | 000288333800015 | - |
dc.identifier.bibliographicCitation | APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, v.89, no.6, pp.1807 - 1819 | - |
dc.relation.isPartOf | APPLIED MICROBIOLOGY AND BIOTECHNOLOGY | - |
dc.citation.title | APPLIED MICROBIOLOGY AND BIOTECHNOLOGY | - |
dc.citation.volume | 89 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1807 | - |
dc.citation.endPage | 1819 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.subject.keywordPlus | TUMOR-TARGETED SALMONELLA | - |
dc.subject.keywordPlus | ESCHERICHIA-COLI K12 | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | ATTENUATED SALMONELLA | - |
dc.subject.keywordPlus | NECROSIS-FACTOR | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | CYTOSINE DEAMINASE | - |
dc.subject.keywordPlus | CISPLATIN TOXICITY | - |
dc.subject.keywordPlus | ADJUVANT THERAPY | - |
dc.subject.keywordPlus | INTERFERON-ALPHA | - |
dc.subject.keywordAuthor | Antitumor effects | - |
dc.subject.keywordAuthor | Tumor treatments | - |
dc.subject.keywordAuthor | TNF-alpha | - |
dc.subject.keywordAuthor | Salmonella typhimurium | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.